GlassScriptPhysician profile
Chirag Patel
NPI 1205981750
$2,416.75
in general payments reported to CMS, 2019-2025
35 companies · $332 in 2025
The $332 reported for 2025 was more than what a typical Internal Medicine provider received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $318 · 2020: $227 · 2021: $280 · 2022: $387 · 2023: $537 · 2024: $335 · 2025: $332.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,204.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,204.35 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Jazz Pharmaceuticals INC. | $236.53 | 2020-2024 | |
| Lilly USA, LLC | $203.70 | 2023-2025 | Kisunla, Amyvid, Emgality |
| Allergan, INC. | $183.55 | 2019-2021 | |
| Acorda Therapeutics, INC | $171.47 | 2020-2023 | Ampyra, Inbrija |
| Biogen, INC. | $131.93 | 2019-2023 | Tysabri, Vumerity |
| Novo Nordisk INC | $126.87 | 2019-2023 | Wegovy |
| Otsuka America Pharmaceutical, INC. | $125.00 | 2025 | Rexulti |
| Sk Life Science, INC. | $124.99 | 2023 | Xcopri |
| Avadel Cns Pharmaceuticals, LLC | $118.09 | 2025 | Lumryz |
| Janssen Pharmaceuticals, INC | $111.18 | 2021 | |
| Merz Pharmaceuticals, LLC | $108.05 | 2022-2023 | Xeomin |
| Kyowa Kirin, INC. | $67.02 | 2022 | |
| Lundbeck LLC | $65.81 | 2021-2022 | |
| Itamar Medical INC | $59.57 | 2022 | |
| Abbvie INC. | $51.44 | 2023-2025 |
Show all 35 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Corium, LLC | $46.25 | 2022-2023 | Adlarity |
| Ipsen Biopharmaceuticals, INC | $45.69 | 2021-2025 | Iqirvo |
| Teva Pharmaceuticals USA, INC. | $45.40 | 2019-2022 | |
| Biohaven Pharmaceutical Holding Company LTD. | $42.76 | 2022 | |
| Scilex Pharmaceuticals INC. | $37.98 | 2020 | |
| Adamas Pharmaceuticals, INC. | $33.40 | 2019-2020 | |
| Catalyst Pharmaceuticals, INC. | $32.95 | 2023 | Fycompa |
| Amgen INC. | $28.97 | 2023 | Amjevita, Avsola |
| Upsher-Smith Laboratories LLC | $27.36 | 2019 | |
| Alfasigma USA, INC. | $26.80 | 2021 | |
| Avanir Pharmaceuticals, INC. | $22.65 | 2019 | |
| Axsome Therapeutics, INC. | $19.26 | 2023 | Sunosi |
| Abbott Laboratories | $18.32 | 2020 | |
| Harmony Biosciences LLC | $18.31 | 2020 | |
| Takeda Pharmaceuticals U.S.A., INC. | $18.24 | 2019 | |
| Amneal Pharmaceuticals LLC | $17.58 | 2022 | |
| Eisai INC. | $15.82 | 2024 | |
| Vertical Pharmaceuticals, LLC | $13.79 | 2019 | |
| Novartis Pharmaceuticals Corporation | $12.27 | 2021 | |
| Impel Pharmaceuticals LLC | $7.75 | 2024 | Trudhesa |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Chirag Patel listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.